SRNE Key Statistics, Chart & Performance
The current stock price of SRNE is 0.3073 USD. In the past month the price decreased by -69.57%. In the past year, price decreased by -88.14%.
SRNE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.77B | ||
| AMGN | AMGEN INC | 15.1 | 177.79B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.98 | 118.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.86 | 53.69B | ||
| INSM | INSMED INC | N/A | 37.34B | ||
| NTRA | NATERA INC | N/A | 34.33B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.05 | 21.65B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About SRNE
Company Profile
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 799 full-time employees. The company went IPO on 2007-01-19. The Company’s segments include Sorrento Therapeutics and Scilex. Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company’s immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical- stage immuno-cellular therapies (CAR-T, DAR-T), antibody-drug conjugates (ADCs) and clinical-stage oncolytic virus (Seprehvir). The firm is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS, and diagnostic test solutions, including COVITRACK and COVISTIX.
Company Info
SORRENTO THERAPEUTICS INC
4955 Directors Place
San Diego CALIFORNIA 92121 US
CEO: Henry Ji
Employees: 799
Phone: 18582034100.0
SORRENTO THERAPEUTICS INC / SRNE FAQ
What does SORRENTO THERAPEUTICS INC do?
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 799 full-time employees. The company went IPO on 2007-01-19. The Company’s segments include Sorrento Therapeutics and Scilex. Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company’s immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical- stage immuno-cellular therapies (CAR-T, DAR-T), antibody-drug conjugates (ADCs) and clinical-stage oncolytic virus (Seprehvir). The firm is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS, and diagnostic test solutions, including COVITRACK and COVISTIX.
Can you provide the latest stock price for SORRENTO THERAPEUTICS INC?
The current stock price of SRNE is 0.3073 USD. The price decreased by -20.26% in the last trading session.
Does SRNE stock pay dividends?
SRNE does not pay a dividend.
What is the ChartMill technical and fundamental rating of SRNE stock?
SRNE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for SRNE stock?
The Revenue of SORRENTO THERAPEUTICS INC (SRNE) is expected to grow by 3.85% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for SRNE stock?
You can find the ownership structure of SORRENTO THERAPEUTICS INC (SRNE) on the Ownership tab.
SRNE Technical Analysis
SRNE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SRNE. Both the profitability and financial health of SRNE have multiple concerns.
SRNE Financial Highlights
Over the last trailing twelve months SRNE reported a non-GAAP Earnings per Share(EPS) of -1.43. The EPS decreased by -20.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.14 |
SRNE Forecast & Estimates
9 analysts have analysed SRNE and the average price target is 7.82 USD. This implies a price increase of 2444.75% is expected in the next year compared to the current price of 0.3073.
For the next year, analysts expect an EPS growth of 15.83% and a revenue growth 3.85% for SRNE